Driven by the Patients & Families to Find Effective Heart Failure Therapies

 3-D Human micro tissue technologies accelerating personalized drug discovery and development.
These innovations assist our partners deliver better medicines faster and cost effectively.

Precision Medicine Developer Using Patient-Derived 3D Micro-Tissues

InvivoSciences, Inc. (IVS) is a precision medicine company personalizing the drug development process by introducing the next-generation, best-in-class patient-derived and gene-edited human samples, including automated, scalable, functional 3D engineered micro-human heart tissue platform. Our unique integration of cell & tissue handling automation, tissue phenotyping assays, computational biology (AI), and human organ/tissue data enables rapid identification of safety and efficacy profile of a given treatment for specific patient group significantly cost-effective prior to expensive clinical trials. IVS’s technology for matchmaking the best treatment for the patient group will expedite the early discovery and clinical trials as well as support post-product launch monitoring. Thus, our approach brings tremendous value to pharmaceutical developers who are evaluating the safety and efficacy of new drug candidates before investing significant resources in human trials and who wants to increase their success rate of drug approvals. As such the breakthrough technology can dramatically help 1) mitigate the historically high risk of clinical trial failure because of the treatment-induced arrhythmia, and heart failure and 2) develop patient-specific heart failure treatments.


Using IVS approach, we identified a new class of repurposing drug pipelines to treat cardiac fibrosis in genetically defined heart failure. Expanding disease models of various genetically defined heart failure will allow us to identify and validate new or existing targets to treat the conditions. 

View our Pipeline

John’s Micro Hearts Find the Best Treatment for John

Our founders’ personal experience drove us to start doing what we do now. Thanks to the US National Institute of Health and generous contributors. Their long-term and extensive support enabled IVS to develop and validate human induced pluripotent stem cell (iPSC) derived micro-heart tissue called NuHeart™. IVS’s core competencies include an automated process of mass-producing micro NuHearts™ derived from various lines of patient-specific and gene-edited iPSCs and their high-throughput phenotypic assay platform.

Illustration courtesy of TEDx Talk

Why we do what we do?

InvivoSciences, Inc. (IVS’s) vision is to transform the traditional approaches and develop cost-effective, safe, and effective precision medicines for patients with inherited heart failure.
InvivoSciences, Inc. is an innovative drug discovery company with several preclinical pipelines.

Areas of Contribution

Aging related Heart Failure

Rare and Genetically Defined Heart Failure

Cardio-Oncology: Cancer Therapy-induced Heart Failure

Technology Applications

HTP Phenotyping

A unique combination of our pioneering biomechanical assays and ultra-rapid optical devices collects high-content data of cell and tissue physiology.

Rare Disease Modeling

Using human induced pluripotent stem cell and gene-editing technologies, IVS supports generation organ models that recapitulate mono-genetic disorders.

Automation

Standardized cell and tissue sample preparations set us apart. IVS developed automated cell and tissue handling device to reduce variability among scientists.

System Biology and AI

The power of artificial intelligence (AI) can be unleashed only if AI have enough data. InvivoSciences is collecting and analyzing the big data to train the AI to predict physiological responses of a given treatment.

Award Winning Technology

InvivoSciences’
Innovation is award winning

InvivoScience’s innovations in tissue-based assay R&D have been winning awards throughout the years.

SEE ALL OUR AWARDS
Read our White Paper

Human Engineered Tissue:

Medical Countermeasures For Public Health
& CBRN Emergencies

Read now

Connect with us! It will only take a minute